Azurrx Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>AB</div>
AZRX -- USA Stock  

USD 1.51  0.18  10.65%

The upcoming quarterly report is expected on the 15th of February 2021. The stock experiences an active upward rally. AzurRx BioPharma Shareholders Equity is fairly stable at the moment as compared to the past year. AzurRx BioPharma reported Shareholders Equity of 5.31 Million in 2020. Total Liabilities is likely to rise to about 4.1 M in 2021, whereas Average Assets are likely to drop slightly above 9.9 M in 2021. As many baby boomers are still indifferent towards healthcare space, it makes sense to break down AzurRx BioPharma as a unique choice for millenniums. We will evaluate why recent AzurRx BioPharma price moves suggest a bounce in February.
Published over a month ago
View all stories for Azurrx Biopharma | View All Stories
Should I hold on to my AzurRx (NASDAQ:AZRX) position?
This firm currently holds 105.62 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. The company has a current ratio of 4.3, suggesting that it is liquid enough and is able to pay its financial obligations when due.
Azurrx Biopharma financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Azurrx Biopharma, including all of Azurrx Biopharma's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Azurrx Biopharma assets, the company is considered highly leveraged. Understanding the composition and structure of overall Azurrx Biopharma debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding Azurrx Total Debt

Azurrx Biopharma liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Azurrx Biopharma has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Azurrx Biopharma balance sheet include debt obligations and money owed to different Azurrx Biopharma vendors, workers, and loan providers. Below is the chart of Azurrx main long-term debt accounts currently reported on its balance sheet.
You can use Azurrx Biopharma financial leverage analysis tool to get a better grip on understanding its financial position

How important is Azurrx Biopharma's Liquidity

Azurrx Biopharma financial leverage refers to using borrowed capital as a funding source to finance Azurrx Biopharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Azurrx Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Azurrx Biopharma's total debt and its cash.

Acquisition by Oakes Gregory of 41237 shares of AzurRx BioPharma subject to Rule 16b-3

Legal trades by Azurrx Biopharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
AzurRx insider trading alert for grant of options (right to buy) by Oakes Gregory, the corporate stakeholder, on 6th of January 2021. This event was filed by Azurrx Biopharma Inc with SEC on 2021-01-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

The current price rise of AzurRx BioPharma could raise concerns from investors as the firm it trading at a share price of 1.87 on 156,335,895 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 10.9. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the AzurRx BioPharma partners.

Liabilities Breakdown

3.7 M
Current Liabilities
1.2 M
Long-Term Liabilities
Total Liabilities4.06 Million
Current Liabilities3.67 Million
Long-Term Liabilities1.22 Million

Can AzurRx BioPharma build up on the current rise?

The mean deviation is down to 3.4 as of today. AzurRx BioPharma is displaying above-average volatility over the selected time horizon. Investors should scrutinize AzurRx BioPharma independently to ensure intended market timing strategies are aligned with expectations about AzurRx BioPharma volatility.

Our Final Take On AzurRx BioPharma

While other companies within the biotechnology industry are still a little expensive, even after the recent corrections, AzurRx BioPharma may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor exit any shares of AzurRx BioPharma at this time. The AzurRx BioPharma risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to AzurRx BioPharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Azurrx Biopharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com